IOF Regional 7th Asia-Pacific Osteoporosis Conference Sydney, Australia 2018 – Oral Communications Abstracts
- 3 Downloads
T-SCORE AS AN INDICATOR OF FRACTURE RISK ON THERAPY: EVIDENCE FROM ROMOSOZUMAB VS. ALENDRONATE TREATMENT IN THE ARCH TRIAL
F. C. Cosman1, E. M. Michael2, P. E. Ebeling3, E. H. Hesse4, N. N. Napoli5, B. C. Crittenden6, M. R. Rojeski6, W. Y. Yang6, C. L. Libanati7, S. F. Ferrari8
1Columbia University, New York, USA, 2New Mexico Clinical Research & Osteoporosis Center, Albuquerque, USA, 3Monash University, Melbourne, Australia, 4University Medical Center Hamburg-Eppendorf, Hamburg, Germany, 5Campus Bio-Medico University of Rome, Rome, Italy, 6Amgen Inc, Thousand Oaks, USA, 7UCB Pharma, Brussels, Belgium, 8Geneva University Hospital, Geneva, Switzerland
Postmenopausal women with osteoporosis and prior fragility fracture were randomized 1:1 to receive Romo 210mg SC QM or ALN 70mg PO QW for 12 months, followed by open-label (OL) ALN 70mg PO QW for ≥12 months. We examined change from baseline in BMD and T-scores at 12 months and the relationship between total hip (TH) T-scores at month 12...